Prospective randomized study of the evaluation of the efficacy and the invasiveness in the treatment of benign prostatic hyperplasia with transurethral thulium laser surgery and transurethral resection of the prostate

Prospective randomized study of the evaluation of the efficacy and the invasiveness in the treatment of benign prostatic hyperplasia with transurethral thulium laser surgery and transurethral resection of the prostate - Prospective randomized study of the evaluation of the efficacy and the invasiveness in the treatment of benign prostatic hyperplasia with ThuLEP and TUR-P

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000039731

Enrollment

140

Registered

2020-03-09

Start date

2017-03-07

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Benign Prostatic Hyperplasia

Interventions

Transurethral thulium laser surgery, about 2 hours Transurethral resection of the prostate, about 2 hours

Eligibility

Sex/Gender

Male

Inclusion criteria

Inclusion criteria: 1. Age with and larget than 50 years old, less than 90 years old 2. Patient who were diagnosed with benign prostatic hyperplasia 3. Patient who has blodder outlet obstruction due to benign prostatic hyperplasia 4. Patient who who underwent this procedure provided informed consent

Exclusion criteria

Exclusion criteria: 1. Patient who has other disease which has effect to the urinary function 2. Patient who has influence due to pre-operative treatment 3. Patients who was regarded as inadequacy for the present study

Design outcomes

Primary

Measure	Time frame
1. Influence to the urinary function 2. Ocurrence of complications	—

Countries

Japan

Contacts

Public ContactSunao Shoji

Tokai University School of Medicine Department of Urology

sunashoj@mail.goo.ne.jp0463-93-1121

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026